Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AFYA Stock Forecast 2025-2026
$18.91
Current Price
$1.70B
Market Cap
Buy 3
Hold 2
Sell 4
Wall St Analyst Ratings
Distance to AFYA Price Targets
+28.1%
To High Target of $24.21
+2.3%
To Median Target of $19.33
-15.4%
To Low Target of $16.00
AFYA Price Momentum
-3.0%
1 Week Change
+4.5%
1 Month Change
+3.2%
1 Year Change
+19.1%
Year-to-Date Change
-5.0%
From 52W High of $19.90
+30.2%
From 52W Low of $14.52
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Afya (AFYA) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on AFYA and similar high-potential opportunities.
Latest AFYA Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, AFYA has a neutral consensus with a median price target of $19.33 (ranging from $16.00 to $24.21). The overall analyst rating is Hold (5.3/10). Currently trading at $18.91, the median forecast implies a 2.3% upside. This outlook is supported by 3 Buy, 2 Hold, and 4 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AFYA Analyst Ratings
3
Buy
2
Hold
4
Sell
AFYA Price Target Range
Low
$16.00
Average
$19.33
High
$24.21
Current: $18.91
Latest AFYA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AFYA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 11, 2025 | Morgan Stanley | Mauricio Cepeda | Underweight | Downgrade | $17.00 |
| Jan 31, 2025 | Citigroup | Leandro Bastos | Sell | Downgrade | $15.00 |
| Jan 17, 2025 | JP Morgan | Marcelo Santos | Neutral | Maintains | $20.50 |
| Dec 3, 2024 | Goldman Sachs | Gustavo Miele | Sell | Initiates | $16.00 |
| Aug 30, 2024 | UBS | Andre Salles | Neutral | Initiates | $19.50 |
| Jun 21, 2024 | Morgan Stanley | Mauricio Cepeda | Equal-Weight | Maintains | $19.00 |
| Jan 22, 2024 | Morgan Stanley | Javier Martinez | Equal-Weight | Downgrade | $23.00 |
| Nov 27, 2023 | JP Morgan | Marcelo Santos | Neutral | Downgrade | $23.00 |
| Oct 13, 2023 | Morgan Stanley | Javier Martinez | Overweight | Upgrade | $20.50 |
| Nov 22, 2022 | Credit Suisse | Mauricio Cepeda | Outperform | Maintains | $18.00 |
| Aug 23, 2022 | Credit Suisse | Outperform | Upgrade | $0.00 | |
| Apr 8, 2022 | Credit Suisse | Mauricio Cepeda | Outperform | Upgrade | $19.00 |
| Mar 7, 2022 | UBS | Maria Tereza Azevedo | Buy | Maintains | $21.00 |
| Jul 21, 2021 | Morgan Stanley | Javier Martinez | Equal-Weight | Downgrade | $28.50 |
| Apr 15, 2021 | UBS | Buy | Upgrade | $0.00 | |
| Feb 4, 2021 | JP Morgan | Overweight | Upgrade | $0.00 | |
| Oct 19, 2020 | JP Morgan | Neutral | Downgrade | $0.00 | |
| Sep 28, 2020 | Goldman Sachs | Buy | Upgrade | $0.00 | |
| Aug 19, 2020 | Credit Suisse | Neutral | Initiates | $0.00 | |
| May 20, 2020 | UBS | Neutral | Downgrade | $0.00 |
Afya Ltd. (AFYA) Competitors
The following stocks are similar to Afya based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Afya Ltd. (AFYA) Financial Data
Afya Ltd. has a market capitalization of $1.70B with a P/E ratio of 14.2x. The company generates $608.75M in trailing twelve-month revenue with a 19.8% profit margin.
Revenue growth is +16.4% quarter-over-quarter, while maintaining an operating margin of +39.8% and return on equity of +16.8%.
Valuation Metrics
Market Cap
$1.70B
Enterprise Value
$668.29M
P/E Ratio
14.2x
PEG Ratio
11.1x
Price/Sales
0.5x
Growth & Margins
Revenue Growth (YoY)
+16.4%
Gross Margin
+69.8%
Operating Margin
+39.8%
Net Margin
+19.8%
EPS Growth
+23.9%
Financial Health
Cash/Price Ratio
+67.7%
Current Ratio
1.4x
Debt/Equity
72.1x
ROE
+16.8%
ROA
+8.2%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Afya Ltd. (AFYA) Business Model
About Afya Ltd.
What They Do
Provides medical education services in Brazil.
Business Model
Afya Ltd. generates revenue by offering undergraduate and graduate programs in medicine and related healthcare disciplines. The company combines traditional classroom learning with digital tools to enhance the educational experience, catering to the growing demand for skilled healthcare professionals in Brazil.
Additional Information
The company plays a crucial role in addressing the needs of Brazil's expanding healthcare market and supports the continuum of education from entry-level training to advanced specialties, positioning itself as a key player in the medical education sector.
Company Information
Sector
Consumer Defensive
Industry
Education & Training Services
Employees
0
CEO
Country
Brazil
IPO Year
2019
Website
www.afya.com.brAfya Ltd. (AFYA) Latest News & Analysis
Latest News
Quick Summary
Afya Limited's Q1 results show a 16% YoY revenue growth, boosted by acquisitions and organic growth, though long-term risks include market saturation and increased competition in Brazil's medical education sector.
Why It Matters
Afya Limited's solid growth may attract short-term interest, but long-term risks from market saturation and increasing competition could impact future profitability and valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Bajaj Finance and MercadoLibre posted strong quarterly gains. Cloudflare shows durable growth, while Nvidia faces stock correction amid AI concerns but retains strong performance and conviction.
Why It Matters
Strong earnings from Bajaj Finance and MercadoLibre indicate robust growth potential. Cloudflare's unique offerings and Nvidia's resilience amid AI adoption concerns suggest promising long-term investments.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Afya Limited (NASDAQ: AFYA) will host its Q1 2025 earnings conference call on May 8, 2025, at 5:00 PM ET, featuring CEO Virgilio Gibbon and CFO Luis Andre Blanco.
Why It Matters
Upcoming earnings calls provide insights into Afya Limited's financial health and strategic direction, impacting investor sentiment and stock performance. Key management presence signals transparency.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Afya Limited (Nasdaq: AFYA) reported its Q1 2025 financial results, with net revenue figures released in Brazilian Reais, adhering to IFRS standards. Further details are pending.
Why It Matters
Afya Limited's Q1 2025 financial results reflect its performance and growth potential in the Brazilian medical education sector, impacting investor sentiment and stock valuation.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Afya Limited announced the completion of its acquisition of Faculdade Masterclass Ltda., enhancing its position in Brazil's medical education sector.
Why It Matters
Afya's acquisition of Faculdade Masterclass enhances its market position in medical education, potentially driving revenue growth and improving investor confidence in its future performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Afya Limited (Nasdaq: AFYA) announced its first cash dividend of R$129.8 million, 20% of its 2024 net income of R$648.9 million, to be distributed on March 12, 2025.
Why It Matters
Afya Limited's declaration of a cash dividend signals financial health and profitability, potentially attracting investors seeking income and indicating strong future performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About AFYA Stock
What is Afya Ltd.'s (AFYA) stock forecast for 2025?
Based on our analysis of 8 Wall Street analysts, Afya Ltd. (AFYA) has a median price target of $19.33. The highest price target is $24.21 and the lowest is $16.00.
Is AFYA stock a good investment in 2025?
According to current analyst ratings, AFYA has 3 Buy ratings, 2 Hold ratings, and 4 Sell ratings. The stock is currently trading at $18.91. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AFYA stock?
Wall Street analysts predict AFYA stock could reach $19.33 in the next 12 months. This represents a 2.3% increase from the current price of $18.91. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Afya Ltd.'s business model?
Afya Ltd. generates revenue by offering undergraduate and graduate programs in medicine and related healthcare disciplines. The company combines traditional classroom learning with digital tools to enhance the educational experience, catering to the growing demand for skilled healthcare professionals in Brazil.
What is the highest forecasted price for AFYA Afya Ltd.?
The highest price target for AFYA is $24.21 from at , which represents a 28.1% increase from the current price of $18.91.
What is the lowest forecasted price for AFYA Afya Ltd.?
The lowest price target for AFYA is $16.00 from at , which represents a -15.4% decrease from the current price of $18.91.
What is the overall AFYA consensus from analysts for Afya Ltd.?
The overall analyst consensus for AFYA is neutral. Out of 8 Wall Street analysts, 3 rate it as Buy, 2 as Hold, and 4 as Sell, with a median price target of $19.33.
How accurate are AFYA stock price projections?
Stock price projections, including those for Afya Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 23, 2025 11:04 AM UTC